NEW ORLEANS — Rosuvastatin reduced the risk of major cardiovascular events in healthy persons with elevated levels of high-sensitivity C-reactive protein and LDL cholesterol levels below current treatment thresholds in an international study of nearly 18,000 patients.
PREVIEW